John Libbey Eurotext

Nanotechnology may provide hope for patients with glucose transporter type 1 deficiency syndrome Volume 24, issue 3, June 2022

Figures

  • Figure 1.
Authors
1 Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
2 Jefferson Comprehensive Epilepsy Center, Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA
3 Department of Medical Nanotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran
* Correspondence: Ali A. Asadi-Pooya

Glucose transporter type 1 deficiency syndrome (Glut1DS) is a genetic disorder of the cerebral energy supply system. Glucose transport across the blood-brain barrier (BBB) and astrocyte plasma membrane is exclusively made possible by glucose transporter type 1 (Glut-1) [1]. Patients with Glut1DS often present with drug-resistant epilepsy (with multiple seizure types) and deceleration of head growth during infancy; impaired development and complex movement disorders (e.g., ataxia, dystonia, chorea, [...]